MondegarAI
Lion Point Capital, LP

Q4 2024 · 13F-HR

Lion Point Capital, LPholdings as filed

Filed 2025-02-14 · accession 0001013594-25-000268

$19.1M
Reported value
19
Positions
2024-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
457669307INSMINSMED INC$2.5M13.3%36,700CommonSOLE
59935V107MISTMILESTONE PHARMACEUTICALS IN$2.4M12.7%1,025,806CommonSOLE
374163103GERNGERON CORP$1.8M9.27%500,000CommonSOLE
039697107ARDXARDELYX INC$1.7M8.90%335,400CommonSOLE
31447P100FENCFENNEC PHARMACEUTICALS INC$1.2M6.48%195,700CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$1.1M5.79%40,300CommonSOLE
603170101MLYSMINERALYS THERAPEUTICS INC$972,4905.09%79,000CommonSOLE
G52694109KNSAKINIKSA PHARMACEUTICALS LTD$907,9024.75%45,900CommonSOLE
G1110E107BHVNBIOHAVEN LTD$847,8454.44%22,700CommonSOLE
08205P209BNTCBENITEC BIOPHARMA INC$783,0604.10%62,000CommonSOLE
87164F105SNDXSYNDAX PHARMACEUTICALS INC$727,1003.81%55,000CommonSOLE
471871202JSPRJASPER THERAPEUTICS INC$684,1603.58%32,000CommonSOLE
G29687103AVDLAVADEL PHARMACEUTICALS PLC$672,6403.52%64,000CommonSOLE
254604101IRONDISC MEDICINE INC$672,0403.52%10,600CommonSOLE
09609G209BLE0BLUEBIRD BIO INC$658,1263.45%78,912CommonSOLE
03969K108ARQTARCUTIS BIOTHERAPEUTICS INC$644,9593.38%46,300CommonSOLE
75901B107RGNXREGENXBIO INC$446,4082.34%57,750CommonSOLE
81750R102MCRB1EURSERES THERAPEUTICS INC$283,1721.48%340,761CommonSOLE
85209E109SPRUCE BIOSCIENCES INC$31,5000.16%75,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.